Background
Endometrial cancer is the most common gynecologic malignancy in the U.S., with advanced-stage disease accounting for significant morbidity and mortality. Molecular profiling has become pivotal in guiding treatment decisions, particularly for identifying mismatch repair (MMR) deficiencies, TP53 mutations, and POLE mutations. However, the cost and efficiency of universal next-generation sequencing (NGS) versus selective testing strategies remain debated.
